Tecedor et al. used directed evolution to engineer AAVs with enhanced ependymal and brain delivery after injection into the cerebrospinal fluid. I think it would be interesting to try lumbar puncture delivery of these AAVs as well to see if they maintain decent biodistribution. (See my other post about Hinderer et al.’s paper: https://doi.org/10.1016/j.omtm.2020.04.012).

AAV capsid variants enriched for transduction of ventricular lining cells and brain parenchyma reduce the dose required for gene therapy to the CNS.